Arcadia Biosciences progresses towards profitability after restructuring

of our business by selling some non-core assets. This move has allowed us to streamline our operations and concentrate on areas with greater potential for growth. This year, Arcadia saw an increase in revenue compared to 2023. The improvements are a direct result of our focus on higher-performing products. We are excited about the momentum we are building and believe we are now better positioned for future profitability. During the fourth quarter, we continued to invest in research and development. This investment supports our commitment to bring innovative products to market. We are optimistic about upcoming projects that could significantly impact our revenue. We appreciate the support from our investors and partners throughout this journey. Their trust has been crucial as we worked to stabilize and enhance our business. Going forward, we remain dedicated to transparency and will keep all stakeholders informed about our progress. In summary, 2024 has been a transformative year for Arcadia. We are confident that our strategies will lead to sustainable growth. Thank you for joining our call today, and we look forward to reporting on our future successes.